Noida-based Jubilant Life Sciences plans to launch remdesivir in a tablet form. The antiviral drug, which is being used to treat Covid-19 patients, is currently administered intravenously.
The pharmaceutical company has sought permission of the Drugs Controller General of India (DCGI) to launch remdesivir in a tablet form. In a meeting held on August 25, the company had presented its proposal to the DCGI.
The company has given bioavailability protocol to the subject expert committee (SEC), which has been set up to evaluate proposals related to Covid-19, according to the minutes of the meeting, a copy of which was seen by ET.